Allergan Sales, LLC
20 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
41
Ending by 2030
May 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 9, 2026The maintenance fee for Synthetic bile acid compositions and methods (US 9,050,349) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.
- 2 fees due Mar 1 to 8, 2027 · next Mar 1
- 3 fees due Apr 6 to 22, 2027 · next Apr 6
- 2 fees due May 12 to 17, 2027 · next May 12
- 1 fee due Jul 21, 2027The maintenance fee for Conditioned Medium and Extracellular Matrix Compositions from Cells Cultured Under Hypoxic Conditions (US 10,538,736) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.
- 1 fee due Aug 16, 2027The maintenance fee for Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions (US 9,259,388) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.
- 1 fee due Oct 28, 2027The maintenance fee for Preparation of Bile Acids and Intermediates Thereof (US 10,633,412) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.
Recent changes
- 3 terms have ended since Aug 19, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,008,338 | Ketorolac Tromethamine Compositions for Treating or Preventing Ocular Pain In force · High confidence | In force | High confidence | |
| US 8,258,142 | Substituted 8-[6-Amino-3-Pyridyl]XANTHINES In force · High confidence | In force | High confidence | |
| US 7,598,379 | Methods for the Synthesis of Unsymmetrical Cycloalkyl Substituted Xanthines In force · High confidence | In force | High confidence | |
| US 8,461,140 | Synthetic bile acid compositions and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 8,546,367 | Synthetic bile acid compositions and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 9,636,349 | Synthetic bile acid compositions and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 11,026,955 | Synthetic bile acid compositions and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 9,050,349 | Synthetic bile acid compositions and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 9,522,155 | Synthetic bile acid compositions and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 8,129,519 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 49: 20 patents in force now held by others · 146 lapsed for an unpaid fee · 469 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 25 abandoned · 32 no status recorded